JP2015516801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516801A5 JP2015516801A5 JP2014561381A JP2014561381A JP2015516801A5 JP 2015516801 A5 JP2015516801 A5 JP 2015516801A5 JP 2014561381 A JP2014561381 A JP 2014561381A JP 2014561381 A JP2014561381 A JP 2014561381A JP 2015516801 A5 JP2015516801 A5 JP 2015516801A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- seq
- cancer
- amino acid
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025538 Malignant ascites Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12159938.5 | 2012-03-16 | ||
| EP12159938 | 2012-03-16 | ||
| PCT/EP2013/054768 WO2013135588A1 (en) | 2012-03-16 | 2013-03-08 | Novel binding molecules with antitumoral activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516801A JP2015516801A (ja) | 2015-06-18 |
| JP2015516801A5 true JP2015516801A5 (enExample) | 2016-04-21 |
| JP6325463B2 JP6325463B2 (ja) | 2018-05-16 |
Family
ID=47844323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561381A Expired - Fee Related JP6325463B2 (ja) | 2012-03-16 | 2013-03-08 | 抗腫瘍活性を有する新規結合分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9593314B2 (enExample) |
| EP (1) | EP2825197B1 (enExample) |
| JP (1) | JP6325463B2 (enExample) |
| KR (1) | KR20140135251A (enExample) |
| CN (1) | CN104284675B (enExample) |
| AU (1) | AU2013231488B2 (enExample) |
| BR (1) | BR112014022932A2 (enExample) |
| CA (1) | CA2865597A1 (enExample) |
| MX (1) | MX354717B (enExample) |
| NZ (1) | NZ629283A (enExample) |
| RU (1) | RU2627185C1 (enExample) |
| WO (1) | WO2013135588A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
| MX376384B (es) | 2013-11-27 | 2025-03-07 | Zymeworks Bc Inc | Construcciones de union a antigenos biespecificas dirigidas a her2. |
| JP2017504325A (ja) * | 2014-01-14 | 2017-02-09 | インテグレイテッド バイオセラピューティクス，インコーポレイテッド | バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法 |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| HUE055424T2 (hu) * | 2014-03-17 | 2021-11-29 | Mitsubishi Tanabe Pharma Corp | Antitest-fynomer konjugátumok |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2968258A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| CN108697779B (zh) * | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| NZ750948A (en) | 2016-11-21 | 2020-06-26 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| WO2019134981A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
| AU2019220395B2 (en) | 2018-02-14 | 2025-12-04 | Abba Therapeutics Ag | Anti-human PD-L2 antibodies |
| RU2018111298A (ru) * | 2018-03-29 | 2019-10-01 | Закрытое Акционерное Общество "Биокад" | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
| WO2020212593A1 (en) | 2019-04-18 | 2020-10-22 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| CA3137882A1 (en) | 2019-05-23 | 2020-11-26 | Tamara SEREDENINA | Anti-tdp-43 binding molecules and uses thereof |
| JP2022537337A (ja) | 2019-06-18 | 2022-08-25 | マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 金属錯体試薬を介するＨｉｓタグ付タンパク質などの標的分子への標識および／または担体の部位特異的、速度論的に不活性なコンジュゲーション |
| CA3161178A1 (en) | 2019-11-20 | 2021-05-27 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Archaeal peptide recombinase - a novel peptide ligating enzyme |
| US20210188990A1 (en) | 2019-12-11 | 2021-06-24 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| TW202221008A (zh) | 2020-08-07 | 2022-06-01 | 瑞士商赫孚孟拉羅股份公司 | 製備蛋白質組成物之方法 |
| JP2023537761A (ja) | 2020-08-14 | 2023-09-05 | エイシー イミューン ソシエテ アノニム | ヒト化抗ｔｄｐ－４３結合分子およびその使用 |
| EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
| WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| EP4405396A2 (en) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| CR20240231A (es) | 2021-11-16 | 2024-07-09 | Ac Immune Sa | Moléculas novedosas para terapias y diagnósticos |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CR20240378A (es) | 2022-02-16 | 2024-10-03 | Ac Immune Sa | Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas |
| WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
| EP4522757A2 (en) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| CN120917043A (zh) | 2023-03-08 | 2025-11-07 | Ac免疫有限公司 | 抗tdp-43结合分子及其用途 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221736A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184205B1 (en) | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| AU2005287404B2 (en) * | 2004-07-22 | 2009-05-07 | Genentech, Inc. | HER2 antibody composition |
| BRPI0515589A (pt) | 2004-09-02 | 2008-07-29 | Genentech Inc | polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit |
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US9513296B2 (en) | 2006-08-21 | 2016-12-06 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| MY188455A (en) | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| EP2464663A4 (en) * | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS |
| CA2772162C (en) * | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| JP6184695B2 (ja) * | 2009-12-04 | 2017-08-23 | ジェネンテック， インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
| BR112012014194A2 (pt) * | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
| CA3051311A1 (en) * | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| WO2012009705A1 (en) * | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
-
2013
- 2013-03-08 MX MX2014011066A patent/MX354717B/es active IP Right Grant
- 2013-03-08 NZ NZ629283A patent/NZ629283A/en not_active IP Right Cessation
- 2013-03-08 KR KR1020147029084A patent/KR20140135251A/ko not_active Ceased
- 2013-03-08 RU RU2014141598A patent/RU2627185C1/ru not_active IP Right Cessation
- 2013-03-08 CA CA2865597A patent/CA2865597A1/en not_active Abandoned
- 2013-03-08 JP JP2014561381A patent/JP6325463B2/ja not_active Expired - Fee Related
- 2013-03-08 BR BR112014022932A patent/BR112014022932A2/pt not_active Application Discontinuation
- 2013-03-08 WO PCT/EP2013/054768 patent/WO2013135588A1/en not_active Ceased
- 2013-03-08 EP EP13708424.0A patent/EP2825197B1/en not_active Not-in-force
- 2013-03-08 US US14/385,729 patent/US9593314B2/en not_active Expired - Fee Related
- 2013-03-08 CN CN201380014237.9A patent/CN104284675B/zh not_active Expired - Fee Related
- 2013-03-08 AU AU2013231488A patent/AU2013231488B2/en not_active Ceased
-
2017
- 2017-03-09 US US15/454,769 patent/US20170281768A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516801A5 (enExample) | ||
| JP2016516789A5 (enExample) | ||
| NZ708182A (en) | Bispecific t cell activating antigen binding molecules | |
| JP2013166763A5 (enExample) | ||
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| MX2014011066A (es) | Moleculas de union novedosas con actividad antitumoral. | |
| JP2020506971A5 (enExample) | ||
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| JP2017140051A5 (enExample) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2014088414A5 (enExample) | ||
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| JP2019535234A5 (enExample) | ||
| RU2019118257A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2014518615A5 (enExample) | ||
| JP2015119705A5 (enExample) | ||
| JP2014524445A5 (enExample) | ||
| RU2014109557A (ru) | Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| FI3227342T4 (fi) | Proteiininen heterodimeeri ja sen käyttö | |
| JP2011510632A5 (enExample) | ||
| JP2017525698A5 (enExample) | ||
| HRP20211788T1 (hr) | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica | |
| JP2013540696A5 (enExample) |